《大行報告》匯豐研究下調吉利(00175.HK)目標價至23元 評級「買入」
匯豐研究發表報告,指吉利汽車(00175.HK)2022年上半年盈利差過預期,低估了第二季由於封城措施和汽車芯片短缺所造成干擾,導致銷量下跌帶來的毛利率壓力,該行將吉利2022和2023年淨利潤預測分別下調48%和38%,目標價由29元下調至23元,評級「買入」。
匯豐研究指出,吉利的股價自5月底以來已反彈4%,主要受內燃機汽車政策支持和電動車上行週期帶動,銷量勢頭復甦,相信最壞的情況已經過去,由於供應鏈樽頸的逐步消除,電動車上行週期加速,內燃機汽車組合提升,吉利2022年下半年的銷量料將增加,先進車型推出可能會提高銷量,支持毛利率改善和帶動投資收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.